Lv1
86 积分 2024-03-26 加入
Real-world implications of efgartigimod in managing refractory myasthenia gravis
6小时前
待确认
重症先天性结核病1例
13天前
已完结
A comprehensive analysis of the epidemiology and clinical characteristics of anti-LRP4 in myasthenia gravis
1个月前
已完结
Maintenance immunosuppression in myasthenia gravis, an update
1个月前
已完结
Myasthenia gravis and congenital myasthenic syndromes
1个月前
已完结
儿童呼吸道合胞病毒感染致危重症肺炎风险的列线图预测模型
1个月前
已完结
Pediatric Autoimmune Ocular Myasthenia Gravis: Evaluation of Presentation and Treatment Outcomes in a Large Cohort
1个月前
已完结
Juvenile myasthenia gravis in Norway: Clinical characteristics, treatment, and long-term outcome in a nationwide population-based cohort
2个月前
已完结
Safety, efficacy, and tolerability of efgartigimod in patients with generalised myasthenia gravis (ADAPT): a multicentre, randomised, placebo-controlled, phase 3 trial
4个月前
已完结
The generation of antibody-secreting plasma cells
5个月前
已完结
皖公网安备34019202002308
